ProShare Advisors LLC Purchases 1,083 Shares of GeneDx Holdings Corp. $WGS

ProShare Advisors LLC raised its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 39.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 3,850 shares of the company’s stock after buying an additional 1,083 shares during the period. ProShare Advisors LLC’s holdings in GeneDx were worth $355,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Chung Wu Investment Group LLC grew its position in GeneDx by 8.2% in the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock valued at $305,000 after purchasing an additional 250 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares in the last quarter. US Bancorp DE boosted its stake in shares of GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after buying an additional 548 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of GeneDx by 1.6% in the 1st quarter. Acadian Asset Management LLC now owns 36,182 shares of the company’s stock valued at $3,199,000 after acquiring an additional 567 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of GeneDx by 351.5% in the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after acquiring an additional 594 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the subject of several recent research reports. Wall Street Zen cut GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Wells Fargo & Company raised their target price on shares of GeneDx from $95.00 to $140.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 4th. BTIG Research upped their price target on shares of GeneDx from $140.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Piper Sandler increased their price target on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, September 11th. Finally, Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 2nd. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.22.

Insider Transactions at GeneDx

In other news, CFO Kevin Feeley sold 388 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $52,977.52. Following the transaction, the chief financial officer owned 3,757 shares in the company, valued at approximately $512,980.78. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jason Ryan sold 38,072 shares of GeneDx stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director directly owned 103,284 shares of the company’s stock, valued at approximately $13,148,053.20. The trade was a 26.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,375 shares of company stock worth $7,119,247 over the last quarter. Company insiders own 29.60% of the company’s stock.

GeneDx Price Performance

NASDAQ:WGS opened at $146.55 on Friday. The company has a market cap of $4.24 billion, a P/E ratio of 1,628.33 and a beta of 2.01. The firm’s fifty day moving average price is $126.85 and its two-hundred day moving average price is $103.47. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $147.71. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The business had revenue of $116.74 million during the quarter, compared to the consensus estimate of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.